C1QC抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using C1QC mouse mAb (green) and negative control (red).    

  
  

C1QC antibodies target the C1q component of the complement system, a critical mediator of innate immunity. C1q, encoded by the *C1QC* gene, forms part of the C1 complex in the classical complement pathway. It consists of six homologous globular head regions arranged in a hexameric structure, enabling it to bind to antigen-antibody complexes, pathogen surfaces, or apoptotic cells. This binding triggers complement activation, leading to pathogen clearance, inflammation, and immune regulation.

C1QC antibodies are primarily used in research and diagnostics to study C1q's role in autoimmune diseases, infections, and tissue injury. For example, autoantibodies against C1q are strongly associated with systemic lupus erythematosus (SLE), particularly lupus nephritis, where they contribute to glomerular damage. Conversely, genetic deficiencies in C1q are linked to increased susceptibility to infections and autoimmune disorders.

In research, C1QC antibodies help detect C1q deposition in tissues (e.g., renal biopsies) or quantify its levels in serum. They also aid in exploring C1q's non-complement functions, such as synaptic pruning in neurodevelopment or its role in modulating immune tolerance. Recent studies highlight C1q's involvement in neurodegenerative diseases, cancer, and metabolic disorders, broadening the relevance of C1QC antibodies in translational medicine. However, interpreting results requires caution, as C1q can bind nonspecifically to immune complexes or debris, necessitating controlled experimental designs.